HSV-1 can absolutely be a sexually transmitted infection, even though most people still think of it as “just cold sores.” The virus doesn’t care whether it reaches you through a kiss from a relative in childhood or through oral sex with a partner in college. When HSV-1 infects the genitals, which it increasingly does, it behaves as an STI by any clinical definition. The distinction between “oral herpes” and “genital herpes” is really about where the virus sets up shop, not about two fundamentally different diseases.
How HSV-1 Became a Leading Cause of Genital Herpes
For most of human history, the vast majority of people picked up HSV-1 as young children, usually from family members through ordinary non-sexual contact like shared utensils or a kiss on the cheek. By the time those children became sexually active, they already carried antibodies that offered some protection against a second HSV-1 infection at a different body site. That pattern has been shifting. In the United States, childhood HSV-1 seroprevalence has been declining for decades, likely driven by smaller family sizes, less school crowding, and improved hygiene. On the surface, fewer kids getting infected sounds like progress, and in many ways it is, since it means fewer oral-herpes-related complications in childhood. But there’s a catch: more adolescents and young adults are now reaching their sexual debut without any prior HSV-1 exposure, leaving them fully susceptible to genital infection through oral sex.
A 2024 systematic review and meta-analysis of U.S. epidemiological data confirmed this trend, noting that the decline in childhood seroprevalence has been accompanied by rising rates of genital HSV-1 acquisition, primarily through oral-genital contact.
1iScience. Epidemiology of herpes simplex virus type 1 in the United States: Systematic review, meta-analyses, and meta-regressionsIn many sexual health clinics today, HSV-1 accounts for a substantial share of new genital herpes diagnoses, particularly among young women. The virus hasn’t changed; the population’s immunity profile has.
Transmission Without Symptoms
One reason HSV-1 spreads so effectively is that the virus sheds from the skin and mucous membranes even when a person has no visible sores and feels perfectly fine. This asymptomatic shedding is the engine behind most herpes transmission, oral and genital alike.
A study that followed patients with oral HSV-1 found that the virus was detectable in saliva on about a third of days tested, and the shedding typically lasted one to three days at a stretch.
2PubMed. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavityThat means someone with a history of cold sores, or even someone who has never noticed a cold sore but carries the virus, can transmit HSV-1 to a partner’s genitals during oral sex on any given day without any warning signs.
Genital HSV-1 also sheds, though the picture looks somewhat different. A study published in JAMA tracked people in the year following a first genital HSV-1 episode and found oral shedding on roughly 4% of days tested.
3JAMA. Viral Shedding 1 Year Following First-Episode Genital HSV-1 InfectionGenital shedding of HSV-1 tends to be less frequent than genital shedding of HSV-2, which matters for both recurrence and onward transmission. But “less frequent” is not “zero,” and people with genital HSV-1 can still pass the virus to partners, particularly during the first year after infection when shedding rates are highest.
How Genital HSV-1 Differs From Genital HSV-2
If you’re diagnosed with genital herpes, one of the most clinically meaningful questions is which virus is responsible. HSV-1 and HSV-2 both cause genital herpes, and a first outbreak can look and feel nearly identical regardless of type. But from there, the two viruses diverge in important ways.
HSV-2 tends to recur far more often when it’s in the genital area. In the first year after infection, people with genital HSV-2 average about five recurrences, while those with genital HSV-1 average around one.
4JAMA. What Is Genital Herpes?Recurrence rates for both types decline over time, but the gap remains substantial. For many people with genital HSV-1, the first outbreak is the worst they’ll ever experience, and some never have a recognizable recurrence at all.
This difference matters for daily life, for decisions about suppressive medication, and for the risk of transmitting the virus to sexual partners. Someone with genital HSV-1 is shedding less often and recurring less often than someone with genital HSV-2, which translates to a lower (though not negligible) risk of passing it along. It also means that the emotional weight of a genital herpes diagnosis can be heavily influenced by knowing the type, yet many clinics still deliver the diagnosis without specifying which virus was found.
Why Testing Is Trickier Than You’d Expect
Herpes testing carries some frustrating limitations that most people aren’t aware of. The gold standard for diagnosing an active outbreak is a swab of the sore, tested by PCR, which identifies the virus directly and tells you the type. If you have no active lesion, though, you’re left with blood tests that look for antibodies, and those are considerably less reliable.
A study comparing antibody testing against PCR results in patients with recurrent genital herpes found that HSV-1 IgG antibody tests were accurate about 64% of the time for HSV-1-only infections, and HSV-2 IgG tests were accurate only about 38% of the time for HSV-2-only infections.
5PubMed Central. Comparison of the Accuracy of HSV1 and HSV2 Antibody Tests with PCR in the Diagnosis of Recurrent Genital HerpesThese numbers are surprisingly low, and they help explain why the CDC does not recommend routine herpes screening for people without symptoms. False positives and false negatives are common enough to cause real harm, either through unnecessary distress or false reassurance.
Another issue with blood tests is that they can’t tell you where the virus lives. A positive HSV-1 IgG result means you’ve been exposed to HSV-1 at some point in your life, but it can’t distinguish between an oral infection acquired in childhood and a recent genital infection. Since the majority of the adult population carries HSV-1 antibodies, a positive test often raises more questions than it answers. If you’re having genital symptoms that might be herpes, getting a swab during an active episode is far more useful than a blood draw.
Neonatal Herpes and Pregnancy
The one context where the oral-versus-genital distinction and the timing of infection become genuinely high-stakes is pregnancy. Neonatal herpes, though rare, is a serious condition that can cause lasting neurological damage or death. The risk depends heavily on whether the mother has a first-time (primary) genital herpes infection near the time of delivery or a recurrent one.
Research has found that the virus infects roughly half of infants born to mothers with primary genital herpes at the time of delivery, compared with fewer than 5% of infants exposed to recurrent maternal infection.
6PubMed. Relationships between maternal immunity to herpes simplex virus and the risk of neonatal herpesvirus infectionThe reason is straightforward: a first-time infection means the mother hasn’t yet built up antibodies that can cross the placenta and offer the baby some protection. A recurrent infection, by contrast, is accompanied by existing maternal antibodies that significantly reduce the baby’s risk.
This is relevant to the HSV-1-as-STI conversation because a woman who reaches adulthood without prior HSV-1 exposure and then acquires genital HSV-1 from a partner during pregnancy is in the highest-risk category. It’s one more reason why the declining childhood seroprevalence of HSV-1 has a complicated public health dimension.
Antiviral Treatment and Reducing Transmission
Whether HSV-1 is oral or genital, the same antiviral medications are used to manage it. Valacyclovir and acyclovir are the workhorses. For someone having their first genital outbreak, a course of antivirals shortens the episode and reduces severity. For people with frequent recurrences, daily suppressive therapy can substantially cut both outbreak frequency and the amount of virus shed between outbreaks.
A clinical trial found that once-daily valacyclovir reduced genital HSV-2 shedding by about 78% compared to a placebo, dropping the proportion of days with detectable virus from roughly 14% to about 3%.
7PubMed Central. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital HerpesThat trial focused on HSV-2, and less data exists specifically for suppressive therapy’s effect on genital HSV-1 shedding. But because genital HSV-1 already recurs and sheds less frequently than HSV-2, many clinicians reserve daily suppressive therapy for those with frequent outbreaks or specific risk concerns like an HSV-negative partner, rather than prescribing it automatically for everyone with genital HSV-1.
For preventing oral-to-genital transmission, barrier methods matter but have practical limitations. Condoms reduce risk during penetrative sex, and dental dams can theoretically reduce risk during oral sex, but usage rates for dental dams remain low. Researchers have noted that despite their simplicity, dental dams are underutilized, largely because of lack of awareness and unfamiliarity among both patients and health educators.
8PubMed Central. Dental dams in dermatology: An underutilized barrier method of protectionIn practice, most people don’t use dental dams during oral sex, which is one reason oral-to-genital HSV-1 transmission continues to rise even as awareness of genital herpes improves.
The Stigma Problem
Herpes carries a level of social stigma wildly disproportionate to its medical severity. Most people with HSV-1, oral or genital, experience mild symptoms or none at all. Yet the word “herpes” triggers anxiety, shame, and relationship fears that can affect a person’s mental health far more than the virus itself.
Research into genital herpes stigma has identified several distinct dimensions of the experience, including concerns about disclosure to partners, negative self-image, worry about public attitudes, and fear of personal rejection. A study that developed a measurement scale for this stigma found that it correlated with negative emotions, rumination, and lower perceived social support.
9PubMed Central. Genital herpes stigma: Toward the Measurement and Validation of a highly prevalent yet hidden public health problemThe oral-versus-genital framing contributes to this stigma in a particularly illogical way. Someone who gets cold sores on their lip from HSV-1 is treated as having a minor annoyance. Someone who gets the exact same virus on their genitals, often transmitted by the first person, is treated as having a shameful STI. The virus is identical; only the social meaning changes based on where on the body it appears. This stigma can discourage people from getting tested, disclosing to partners, or seeking treatment, all of which make the public health situation worse.
Why Some People Get Constant Cold Sores While Others Never Do
If you’ve ever wondered why one person gets cold sores every few weeks while their sibling (also infected) never seems to get them, genetics plays a real role. Not everyone’s immune system handles HSV-1 identically, and researchers have been mapping which host genes influence outbreak frequency and severity.
A study identified a region dubbed “cold sore susceptibility gene-1” (CSSG-1) and found that certain genetic variants within it were significantly associated with how often people experienced cold sores and how severe those outbreaks felt. Some variants appeared to be protective, meaning carriers had fewer and milder outbreaks.
10PubMed Central. Cold sore susceptibility gene-1 genotypes affect the expression of herpes labialis in unrelated human subjectsSeparately, a twin study investigated several genetic variants previously linked to herpes labialis (the clinical name for cold sores) and found a nominal association between a vitamin D receptor gene variant and both the occurrence and recurrence of cold sores.
11PubMed. Associations between host genetic variants and Herpes Simplex Labialis in the TwinsUK cohortThe vitamin D connection is intriguing but still in early stages; no one should rush to take supplements expecting fewer cold sores based on this alone. The broader takeaway is that herpes is not a level playing field. Two people can carry the same virus and have radically different experiences, and genetics is a major reason why.
HSV-1 and Alzheimer’s Disease
One of the more surprising research threads in recent years links HSV-1 to Alzheimer’s disease. The idea isn’t as far-fetched as it might sound. HSV-1 establishes lifelong latency in nerve cells and periodically reactivates, and the brain is a place where the virus can reach. Researchers have found HSV-1 proteins in brain regions affected by Alzheimer’s, and they’ve proposed that cycles of viral reactivation could contribute to the chronic inflammation, amyloid-beta buildup, and neuronal damage characteristic of the disease.
12PubMed Central. HSV-1 as a Potential Driver of Alzheimer’s DiseaseThe evidence is still being worked out, though, and it doesn’t all point in one direction. A study analyzing data from a large trial in older adults found that participants infected with HSV-1 actually tended to have lower cortical amyloid levels than uninfected participants, particularly among carriers of the APOE4 gene variant that raises Alzheimer’s risk.
13Scientific Reports. Association between herpes simplex virus infection and Alzheimer’s disease biomarkers: analysis within the MAPT trialThat’s the opposite of what the inflammation hypothesis would predict, and it illustrates why this area of research remains unsettled. The relationship between HSV-1 and neurodegeneration is likely more complex than a simple “virus causes disease” story, and it may depend on genetic background, immune status, and how frequently the virus reactivates over a lifetime.
Where Vaccine Research Stands
Despite decades of effort, no approved vaccine exists for HSV-1 or HSV-2. This isn’t for lack of trying. A 2024 literature review identified a dozen vaccine candidates in various stages of development, spanning several different approaches including subunit vaccines, live-attenuated vaccines, DNA vaccines, and mRNA vaccines. Several candidates have shown promising results in animal models or early-phase clinical trials.
14PubMed Central. Toward the Eradication of Herpes Simplex Virus: Vaccination and BeyondOne candidate that has attracted particular attention is a single-cycle vaccine deleted in a key viral surface protein called glycoprotein D. In a mouse model, this vaccine provided complete protection against lethal doses of both HSV-1 and HSV-2 clinical isolates, and no latent virus was detected in vaccinated animals. Traditional subunit vaccines targeting the same protein provided little or no protection by comparison.
15PubMed Central. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2Mouse results don’t always translate to humans, but the mechanism behind this vaccine’s success is interesting: protection correlated with a specific type of antibody that activates immune-cell receptors rather than simply neutralizing the virus. That’s a different strategy from earlier failed candidates and offers some reason for cautious optimism.
The mRNA vaccine platform that proved successful for COVID-19 is also being applied to HSV. Moderna’s mRNA-1608, for instance, is in clinical development. Whether any of these candidates will cross the finish line remains uncertain, but the pipeline is more active and more diverse than at any previous point.
An Ancient Virus With a Long History
HSV-1 has been with humans for an extraordinarily long time. Phylogenetic analysis suggests that HSV-1 co-evolved with the human lineage, diverging alongside our ancestors from other primate species. HSV-2, interestingly, appears to have arrived via a different route: a cross-species jump from the ancestor of modern chimpanzees to an early human ancestor roughly 1.6 million years ago.
16PubMed Central. Evolutionary origins of human herpes simplex viruses 1 and 2More recent work analyzing ancient HSV-1 DNA extracted from archaeological remains has added another layer. Researchers estimated that the diversity of modern Eurasian HSV-1 strains dates to roughly 5,000 years ago, coinciding with the late Neolithic period and the Bronze Age migrations that reshaped European populations.
17PubMed Central. Ancient herpes simplex 1 genomes reveal recent viral structure in EurasiaThe implication is that major population movements may have led to lineage replacement, where new HSV-1 strains carried by migrating groups displaced the strains that had been circulating in earlier populations. The virus, in other words, has its own demographic history that mirrors ours. One speculative but widely discussed trigger for increased HSV-1 transmission during this period is the emergence of romantic kissing as a cultural practice, which would have created a new and efficient transmission route between adults.
Understanding HSV-1’s deep evolutionary history helps explain why the virus is so exquisitely adapted to humans. It has had millions of years to fine-tune its ability to establish latency, evade immune detection, and persist for a host’s entire lifetime without killing them. That evolutionary success is exactly why developing a vaccine has been so difficult: the virus has evolved sophisticated tricks to dodge the immune system, and a vaccine has to somehow outsmart those tricks.